1
|
Triaa N, Znati M, Ben Jannet H, Bouajila J. Biological Activities of Novel Oleanolic Acid Derivatives from Bioconversion and Semi-Synthesis. Molecules 2024; 29:3091. [PMID: 38999041 PMCID: PMC11243203 DOI: 10.3390/molecules29133091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2024] [Revised: 06/17/2024] [Accepted: 06/26/2024] [Indexed: 07/14/2024] Open
Abstract
Oleanolic acid (OA) is a vegetable chemical that is present naturally in a number of edible and medicinal botanicals. It has been extensively studied by medicinal chemists and scientific researchers due to its biological activity against a wide range of diseases. A significant number of researchers have synthesized a variety of analogues of OA by modifying its structure with the intention of creating more potent biological agents and improving its pharmaceutical properties. In recent years, chemical and enzymatic techniques have been employed extensively to investigate and modify the chemical structure of OA. This review presents recent advancements in medical chemistry for the structural modification of OA, with a special focus on the biotransformation, semi-synthesis and relationship between the modified structures and their biopharmaceutical properties.
Collapse
Affiliation(s)
- Nahla Triaa
- Medicinal Chemistry and Natural Products Team, Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity (LR11ES39), Faculty of Science of Monastir, University of Monastir, Avenue of Environment, Monastir 5019, Tunisia; (N.T.); (M.Z.)
- Laboratoire de Génie Chimique, Université Paul Sabatier, CNRS, INPT, UPS, 31062 Toulouse, France
| | - Mansour Znati
- Medicinal Chemistry and Natural Products Team, Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity (LR11ES39), Faculty of Science of Monastir, University of Monastir, Avenue of Environment, Monastir 5019, Tunisia; (N.T.); (M.Z.)
| | - Hichem Ben Jannet
- Medicinal Chemistry and Natural Products Team, Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity (LR11ES39), Faculty of Science of Monastir, University of Monastir, Avenue of Environment, Monastir 5019, Tunisia; (N.T.); (M.Z.)
| | - Jalloul Bouajila
- Laboratoire de Génie Chimique, Université Paul Sabatier, CNRS, INPT, UPS, 31062 Toulouse, France
| |
Collapse
|
2
|
Zengin Kurt B, Öztürk Civelek D, Çakmak EB, Kolcuoğlu Y, Şenol H, Sağlık Özkan BN, Dag A, Benkli K. Synthesis of Sorafenib-Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent. J Med Chem 2024; 67:4463-4482. [PMID: 38471014 PMCID: PMC10983010 DOI: 10.1021/acs.jmedchem.3c01115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 02/09/2024] [Accepted: 02/26/2024] [Indexed: 03/14/2024]
Abstract
Sorafenib, a multiple kinase inhibitor, is widely used as a first-line treatment for hepatocellular carcinoma. However, there is a need for more effective alternatives when sorafenib proves insufficient. In this study, we aimed to design a structure that surpasses sorafenib's efficacy, leading us to synthesize sorafenib-ruthenium complexes for the first time and investigate their properties. Our results indicate that the sorafenib-ruthenium complexes exhibit superior epidermal growth factor receptor (EGFR) inhibition compared to sorafenib alone. Interestingly, among these complexes, Ru3S demonstrated high activity against various cancer cell lines including sorafenib-resistant HepG2 cells while exhibiting significantly lower cytotoxicity than sorafenib in healthy cell lines. Further evaluation of cell cycle, cell apoptosis, and antiangiogenic effects, molecular docking, and molecular dynamics studies revealed that Ru3S holds great potential as a drug candidate. Additionally, when free Ru3S was encapsulated into polymeric micelles M1, enhanced cytotoxicity on HepG2 cells was observed. Collectively, these findings position Ru3S as a promising candidate for EGFR inhibition and warrant further exploration for drug development purposes.
Collapse
Affiliation(s)
- Belma Zengin Kurt
- Faculty
of Pharmacy, Department of Pharmaceutical Chemistry, Bezmialem Vakif University, 34093 Istanbul, Türkiye
| | - Dilek Öztürk Civelek
- Faculty
of Pharmacy, Department of Pharmacology, Bezmialem Vakif University, 34093 Istanbul, Türkiye
| | | | - Yakup Kolcuoğlu
- Faculty
of Science, Department of Chemistry, Karadeniz
Technical University, 61080 Trabzon, Türkiye
| | - Halil Şenol
- Faculty
of Pharmacy, Department of Pharmaceutical Chemistry, Bezmialem Vakif University, 34093 Istanbul, Türkiye
| | | | - Aydan Dag
- Faculty
of Pharmacy, Department of Pharmaceutical Chemistry, Bezmialem Vakif University, 34093 Istanbul, Türkiye
| | - Kadriye Benkli
- Badakbas
Pharmacy, Altintepe str.
Koknarli 6/C, Maltepe, 34840 Istanbul, Türkiye
| |
Collapse
|
3
|
Tahirli S, Aliyeva F, Şenol H, Demukhamedova S, Akverdieva G, Aliyeva I, Veysova S, Sadeghian N, Günay S, Erden Y, Taslimi P, Sujayev A, Chiragov F. Novel complex compounds of nickel with 3-(1-phenyl-2,3-dimethyl-pyrazolone-5)azopentadione-2,4: synthesis, NBO analysis, reactivity descriptors and in silico and in vitro anti-cancer and bioactivity studies. J Biomol Struct Dyn 2024:1-25. [PMID: 38294759 DOI: 10.1080/07391102.2024.2309646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Accepted: 01/18/2024] [Indexed: 02/01/2024]
Abstract
A synthesized azo compound based on 4-amino antipyrine and its complexes with Ni(II) in solution and solid phase is reported. The structures of these compounds have been testified by IR and NMR spectroscopy. The combined experimental and theoretical approach was used. To study the structure and properties of the synthesized compound, as well as its possible complex formation with the Ni(II), ab initio quantum-chemical calculations were carried out using the Hartree-Fock (HF) method with the 6-31 G basis set and the electron density functional theory (DFT) method with hybrid three-parameter potential B3LYP and extended basis set 6-311++G(d,p) taking into account polarization and diffuse functions for all atoms. The geometric, energy, and electronic parameters were calculated and analyzed. The HOMO-LUMO energy gap has been calculated to determine chemical activity. Both complexes had effective inhibition against butyrylcholinesterase and acetylcholinesterase. IC50 values were found as 19.43 and 27.08 µM for AChE, 2.37 and 7.40 µM for BChE, respectively. For the anticancer outcome, high doses of compound E1 inhibited viability by about 40-45%, while this rate was around 65-70% for compound E2 at the same doses. Anticholinesterase and anticancer potential of compounds E1 and E2 also evaluated by in silico techniques. Both compounds show strong binding to VEGFR1, with E2 exhibiting superior inhibitory activity in hAChE and hBChE through shorter and stronger interactions. MD simulations suggest that E2 forms more stable complexes with hAChE and hBChE compared to E1, making it a promising candidate for further exploration in anticancer and anticholinesterase therapies.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
| | - Fargana Aliyeva
- Institute of Chemistry of Additives named after acad. A. M. Guliyev, Baku, Azerbaijan
| | - Halil Şenol
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Bezmialem Vakif University, Fatih, Istanbul, Türkiye
| | | | - Gulnara Akverdieva
- Institute for Physical Problems, Baku State University, Baku, Azerbaijan
| | - Irada Aliyeva
- Institute for Physical Problems, Baku State University, Baku, Azerbaijan
| | | | - Nastaran Sadeghian
- Faculty of Science, Department of Biotechnology, Bartın University, Bartın, Türkiye
| | - Sevilay Günay
- Faculty of Science, Department of Molecular Biology and Genetics, Bartın University, Bartın, Türkiye
| | - Yavuz Erden
- Faculty of Science, Department of Molecular Biology and Genetics, Bartın University, Bartın, Türkiye
| | - Parham Taslimi
- Faculty of Science, Department of Biotechnology, Bartın University, Bartın, Türkiye
| | - Afsun Sujayev
- Institute of Chemistry of Additives named after acad. A. M. Guliyev, Baku, Azerbaijan
| | | |
Collapse
|